MedTrace Logo

Radical Prostatectomy and External Beam Radiotherapy in mCRPC With 223Radium-dicloride (RaProRad)

NCT04110782 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2019-10-01

No results posted yet for this study

Summary

The investigators provided a multicenter analysis aiming to investigate, in a clinical practice setting, the prognostic relevance of previous primary radical prostatectomy (RP) or external beam radiotherapy (RT) in terms of Overall Survival as opposed to patients with no primary treatment performed, in a cohort of patients enrolled in 223-Ra treatment for mCRPC. 223-Ra has been administered from investigators according to the current label authorization and all patients underwent 223-Ra treatment, until disease progression or unacceptable toxicity.

Conditions

Interventions

OTHER

Radium223

55 kBq/ Kg

Sponsors & Collaborators

  • University of Bari Aldo Moro

    collaborator OTHER

  • Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo

    collaborator OTHER

  • University of Bologna

    collaborator OTHER

  • Università degli Studi di Sassari

    collaborator OTHER

  • Ospedale Civile Spirito Santo

    collaborator OTHER

  • Azienda Policlinico Umberto I

    lead OTHER

Principal Investigators

  • Giuseppe De Vincentis, MD, PhD · University of Roma La Sapienza

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2019-06-30
Completion
2020-01-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04110782 on ClinicalTrials.gov